In addition, there may be issues with drug resistance to bevacizumab due to the redundancy of various tumor‐secreted angiogenic factors, including placental growth factor, angiopoietin‐2, epidermal growth factor, and VEGF (Giuliano and Pages, 2013; Kopetz et al., 2010; Labussiere et al., 2016). Here, VEGFA is linked to neoplasm.